Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CLOV stock price vs ZNTL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Needs Annual EPS, ZNTL P/E.
Implied fair value · at CLOV's multiple
Needs Annual EPS is negative, CLOV P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Seven period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CLOVER HEALTH INVESTMENTS, CORP. /DE · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Alignment Healthcare, Inc.
CLOV vs ALHC
Oscar Health, Inc.
CLOV vs OSCR
MOLINA HEALTHCARE, INC.
CLOV vs MOH
CENTENE CORP
CLOV vs CNC
Arcus Biosciences, Inc.
CLOV vs RCUS
Repare Therapeutics Inc.
CLOV vs RPTX
IDEAYA Biosciences, Inc.
CLOV vs IDYA
Mersana Therapeutics, Inc.
CLOV vs MRSN
EXELIXIS, INC.
CLOV vs EXEL
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CLOV can convert its 40.3% revenue growth and 13.4% gross margin into sustained operating improvement, then CLOV looks preferable on a relative valuation basis because it trades at only 1.4x P/S versus ZNTL’s 4.7x and has a much stronger margin profile.
On a P/S basis, CLOV trades at 1.4x versus ZNTL at 4.7x, so CLOV is cheaper on the provided relative valuation metrics despite the model-implied price of $17.70 versus a current price of $5.26. The valuation gap is supported by CLOV’s much larger revenue base and better operating profile, while ZNTL’s negative margins and smaller revenue base justify a much lower quality multiple.
Supporting Metrics
